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Abstract
Purpose Although inflammatory processes play an
essential role in painful intervertebral disc (IVD) degen-
eration, the underlying regulatory mechanisms are not well
understood. This study was designed to investigate the
expression, regulation and importance of specific toll-like
receptors (TLRs)—which have been shown to play an
essential role e.g. in osteoarthritis—during degenerative
disc disease.
Methods The expression of TLRs in human IVDs was
measured in isolated cells as well as in normal or
degenerated IVD tissue. The role of IL-1b or TNF-a in
regulating TLRs (expression/activation) as well as in reg-
ulating activity of down-stream pathways (NF-jB) and
expression of inflammation-related genes (IL-6, IL-8,
HSP60, HSP70, HMGB1) was analyzed.
Results Expression of TLR1/2/3/4/5/6/9/10 was detected
in isolated human IVD cells, with TLR1/2/4/6 being
dependent on the degree of IVD degeneration. Stimulation
with IL-1b or TNF-a moderately increased TLR1/TLR4
mRNA expression (TNF-a only), and strongly increased
TLR2 mRNA expression (IL-1b/TNF-a), with the latter
being confirmed on the protein level. Stimulation with IL-
1b, TNF-a or Pam3CSK4 (a TLR2-ligand) stimulated IL-6
and IL-8, which was inhibited by a TLR2 neutralizing
antibody for Pam3CSK4; IL-1b and TNF-a caused NF-jB
activation. HSP60, HSP70 and HMGB1 did not increase
IL-6 or IL-8 and were not regulated by IL-1b/TNF-a.
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Conclusion We provide evidence that several TLRs are
expressed in human IVD cells, with TLR2 possibly playing
the most crucial role. As TLRs mediate catabolic and
inflammatory processes, increased levels of TLRs may lead
to aggravated disc degeneration, chronic inflammation and
pain development. Especially with the identification of
more endogenous TLR ligands, targeting these receptors
may hold therapeutic promise.
Keywords Intervertebral disc degeneration  Toll-like
receptor TLR activation  Inflammation  Heat shock
protein HSP  High mobility group protein B1 HMGB1
Introduction
Degenerative intervertebral disc (IVD) disease is charac-
terized by degradation of the extracellular matrix [1, 2] and
is associated with increased expression of mediators of
inflammation [3–5]. These mediators of inflammation (e.g.
proinflammatory cytokines) are known to stimulate
expression and activity of matrix degrading enzymes (e.g.
MMP and ADAMTS) as well as to inhibit matrix protein
synthesis, therefore aggravating the disease process [6, 7].
Regulation of proinflammatory cytokines and matrix
degrading enzymes is, therefore, crucial for IVD
homeostasis.
Toll-like receptors (TLRs) are expressed primarily in
cell types that are involved in the first line of defense (e.g.
dendritic cells, macrophages, neutrophils, monocytes or
T/B cells) and have been implicated in innate immunity
and, importantly for this study, in inflammation. During the
past years, TLRs have also been detected in numerous non-
immune cells, e.g. in synovial fibroblasts [8, 9] and chon-
drocytes [10, 11]. In many tissues, expression of certain
TLRs is increased in the presence of degeneration or dis-
ease, e.g. during osteoarthritis [11] or rheumatoid arthritis
[12].
Microbial products are considered to be typical TLR
ligands, indicating their primary role in the activation of
innate immunity [13]. TLR2, for example, recognizes
various Gram-positive bacterial compounds, whereas
lipopolysaccharide LPS (a membrane component of Gram-
negative bacteria) is known to act on TLR4 [14, 15].
However, more recent studies indicate that, in the absence
of infection, TLRs may also recognize endogenous (non-
bacterial) ligands, such as fragments of hyaluronic acid
[16], heat shock protein 60 (HSP60), HSP70, high mobility
group protein B1 (HMGB1) or fatty acids [17–21].
Importantly, HSP60, HSP70 and HMBG1 are expressed in
isolated human IVD cells as well as in native IVD tissue
with different degrees of degeneration (unpublished data).
Ligand-induced initiation of TLR signaling can cause
activation of nuclear factor (NF)-jB and mitogen-activated
protein kinases (MAPKs), leading to increased expression
of proinflammatory cytokines such as IL-1, IL-6, IL-8 and
TNF-a or certain matrix metalloproteinases (MMPs) [7,
22–26]. Therefore, endogenous ligand recognition could
possibly induce catabolic signaling pathways and can thus
directly contribute to degradative processes in the inter-
vertebral disc, even in the absence of microbial compo-
nents. However, no data are present to date that describes
in detail the expression and regulation, as well as the role
and importance, of TLRs in human IVD cells. Therefore,
the aims of this study were:
1. To identify the basal expression of TLR1-10 in isolated
human IVD cells.
2. To identify TLRs whose expression correlates with the
degree of degeneration.
3. To analyze changes in the expression of these ‘‘cor-
related’’ TLRs by inflammatory factors typically
present in vivo during degeneration (IL-1b, TNF-a).
4. To identify whether IL-1b and TNF-a cause activation
of the respective TLR as well as down-stream activa-
tion of NF-jB.
5. To identify whether stress-related proteins HSP60,
HSP70 or HMGB1 play a role in TLR signaling during
inflammatory disc disease.
This study provides evidence that TLR1, TLR2, TLR3,
TLR4, TLR5, TLR6, TLR9 and TLR10 were expressed on
the mRNA level in human IVD cells, with TLR1, TLR2,
TLR4 and TLR6 being dependent on the degree of IVD
degeneration. Exposure to IL-1b and TNF-a primarily
stimulated gene and protein expression of TLR2, its
potential target genes (IL-6, IL-8) and caused NF-jB
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activation. Although no specific TLR2 ligands could be
identified in this study, targeting the TLR2 signaling
pathway could be a promising strategy to reduce inflam-
matory and catabolic processes in the IVD and thus to treat
painful degenerative disc disease.
Methods
Ethical approval and grading
The study was approved by the Gesundheitsdirektion
Kanton Zurich, Switzerland (#EK-16/2005) as well as by
the Charite´ Ethikkommission, Germany (#EA2/087/11).
Informed consent was acquired from the patients in
accordance with the local ethical guidelines.
Using pre-operative MRI, the degree of IVD degenera-
tion was assessed according to Pfirrmann [27] with an
adopted 4-grade classification scale as previously described
[28], i.e. non-degenerated with normal disc height (grade
1), mildly degenerated with slight decrease in disc height
(grade 2), moderately degenerated with a moderate
decrease in disc height (grade 3) or severely degenerated
with extensive loss in disc height (grade 4).
Isolation and culture of intervertebral disc cells
Freshly excised IVD tissue from patients undergoing
spinal surgery due to degenerative disc disease, disc
herniation or sequestration was enzymatically digested for
cell isolation. Due to the degeneration status of most
specimens (moderate to severe: grade 3–4) as well as the
posterior surgical approach used in most cases, no sepa-
ration of nucleus pulposus and annulus fibrosus was
performed. Briefly, biopsies were minced and incubated
with sterile 0.3 % collagenase NB4 (Serva/Promega,
Switzerland) and 0.2 % dispase II (Roche Diagnostics,
Switzerland) in phosphate-buffered saline (PBS) for
4–8 h, the cell suspension was filtered using a 70 lm cell
strainer (BD Bioscience, Switzerland) and expanded up to
passage 3 in a 2D monolayer culture system containing
DMEM/F12 media (Sigma-Aldrich, Switzerland) with
10 % FCS (Tecomedical, Switzerland), penicillin (50 U/
mL), streptomycin (50 lg/mL), and ampicillin (125 ng/
mL) (Invitrogen, Switzerland), with medium changes
twice a week.
Detection of basal TLR mRNA expression
Expanded, but otherwise untreated cells from six patients
with moderate to severe disc degeneration (grade 3–4)
were harvested by trypsin treatment in passage 2 or 3
and mRNA was isolated with the PureLink RNA Mini
Kit (Ambion/Invitrogen, Switzerland) in combination
with DNAse treatment (Invitrogen, Switzerland) accord-
ing to the manufacturer’s recommendation. For each
sample, 1 lg of mRNA was reverse transcribed to
cDNA (Reverse Transcription Reagents, Applied Bio-
systems, Switzerland) and then used for real-time RT-
PCR measurements to detect toll-like receptors TLR1–10
in duplicate measurements as previously described [29].
Eukaryotic 18S ribosomal RNA (rRNA) levels were
measured with a predeveloped primer/probe system
(Applied Biosystems) and used as internal control (DCt
method = Ct of gene of interest - Ct of 18S RNA). For
detailed information on primers see Table 1. Based on
the results, TLR1/2/3/4/5/6/9/10 were further
investigated.
Changes in TLR mRNA expression with the degree
of IVD degeneration
Frozen IVD tissue was obtained from patients undergoing
spinal surgery for symptomatic degenerative disc disease,
disc herniation, or spinal trauma.
Biopsies were allocated to grade 1, 2, 3 or 4 (n = 5–10,
depending on degeneration grade and gene of interest),
pulverized under liquid nitrogen and RNA was extracted
using Trizol extraction (Sigma-Aldrich, Switzerland), fol-
lowed by purification with the PureLink RNA Mini Kit
(Ambion/Invitrogen, Switzerland) as previously described
[30]. Real-time RT-PCR measurement was performed
using TaqMan Gene Expression assays (Applied Biosys-
tems, Switzerland) (chosen based on above mentioned
experiments) as well as of TATA-box binding protein TBP
(internal control). For primer details see Table 1. Gene
expression was normalized to the housekeeping gene TBP
(2-DCt method). Based on the results, TLR1, TLR2, TLR4
and TLR6 were further investigated.
Detection of changes in TLR mRNA expression
upon stimulation with TNF-a or IL-1b
Expanded cells in passages 2 or 3 from biopsies with
degeneration grade 3–4 (i.e. moderate to severe) were
rendered serum free for 2 h and then incubated with IL-1b
and TNF-a in a time- and concentration-dependent manner
to measure gene expression by real-time RT-PCR (n = 5;
only partially identical donors in both experiments,
depending on available cell number). For the time course
experiment, cells were incubated with recombinant IL-1b
(5 ng/ml, Peprotech/LuBioScience, Switzerland) or TNF-a
(100 ng/ml, Peprotech/LuBioScience, Switzerland) for 2, 6
or 18 h in serum-free medium. For the concentration
dependency experiment, cells were treated for 18 h with
different concentrations of IL-1b (0.1, 1, 5, or 10 ng/ml) or
1880 Eur Spine J (2014) 23:1878–1891
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TNF-a (0.1, 1, 10, or 100). All concentrations were shown
to be non-toxic in advance using the MTT assay (data not
shown).
After stimulation, cells were trypsinized, mRNA was
isolated and reverse transcribed as described above. Real-
time RT-PCR measurement was performed using Taq-
Man Gene Expression assays for detection of toll-like
receptors 2, 4 and 6 (chosen based on above mentioned
experiments) as well as of TATA-box binding protein TBP
(internal control). Gene expression was first normalized to
the housekeeping gene before comparing expression of
treated cells to untreated control (2-DDCt method) [31].
Based on the results, TLR2 was further investigated.
Detection of changes in TLR protein expression
upon stimulation with TNF-a or IL-1b
For protein expression analysis, disc cells from three
donors (degeneration grade 3–4) were treated with either
10 ng/ml IL-1b or 100 ng/ml TNF-a for 24 h as
described above (concentration with strongest effect on
gene expression). After stimulation, protein extracts were
prepared from PBS-washed cells by scraping off cells
with 150 ll of SDS lysis buffer (120 mM Tris, 20 %
glycerol, 4 % SDS), followed by sheering using a 27G
needle. In addition, protein extracts of THP1 cells
(monocytic leukemia cell line) were prepared as a
Table 1 Primers/probes
Primers/probes used for the
detection of basal TLR
expression (designed assays) as
well as for the detection of
changes in TLR and IL gene
expression upon stimulation
(TaqMan)
Gene Primers/probes (designed assays) TaqMan
TLR1 F: CAGTGTCTGGTACACGCATGGT Hs00413978_m1
R: TTTCAAAAACCGTGTCTGTTAAGAGA
SYBRGreen dye
TLR2 F: GGCCAGCAAATTACCTGTGTG Hs00152932_m1
R: AGGCGGACATCCTGAACCT
P: TCCATCCCATGTGCGTGGCC (FAM/TAMRA)
TLR3 F: CCTGGTTTGTTAATTGGATTAACGA Hs00152933_m1
R: TGAGGTGGAGTGTTGCAAAGG
P: ACCCATACCAACATCCCTGAGCTGTCAA (FAM/TAMRA)
TLR4 F: CAGAGTTTCCTGCAATGGATCA Hs00152939_m1
R: GCTTATCTGAAGGTGTTGCACAT
P: CGTTCAACTTCCACCAAGAGCTGCCT (FAM/TAMRA)
TLR5 F: TGCCTTGAAGCCTTCAGTTATG
R: CCAACCACCACCATGATGAG
P: CCAGGGCAGGTGCTTATCTGACCTTAACA (FAM/TAMRA)
TLR6 F: GAAGAAGAACAACCCTTTAGGATAGC Hs00271977_s1
R: AGGCAAACAAAATGGAAGCTT
SYBRGreen
TLR7 F: TTTACCTGGATGGAAACCAGCTA
R: TCAAGGCTGAGAAGCTGTAAGCTA
P: AGAGATACCGCAGGGCCTCCCG (FAM/TAMRA)
TLR8 F: TTATGTGTTCCAGGAACTCAGAGAA
R: TAATACCCAAGTTGATAGTCGATAAGTTTG
P: TGATTTCCAGCCCCTGATGCAGC (FAM/TAMRA)
TLR9 F: GGACCTCTGGTACTGCTTCCA
R: AAGCTCGTTGTACACCCAGTCT
P: ACGATGCCTTCGTGGTCTTCGACAAA (FAM/TAMRA)
TLR10 F: CTGATGACCAACTGCTCCAA Hs01935337_s1
R: AGTCTGCGGGAACCTTTCTT
SYBRGreen
IL-6 Hs00174131_m1
IL-8 Hs00174103_m1
18S Hs03003631_g1
TBP Hs00427620_m1
Eur Spine J (2014) 23:1878–1891 1881
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positive control. Protein extracts were separated on a
SDS-polyacrylamide gel and transferred to a PVDF
membrane (Amersham, Switzerland) as previously
described [32]. The membrane was incubated with a
TLR2 antibody (AF2616, R&D Systems, United King-
dom) followed by incubation with an appropriate HRP
secondary antibody before analyzing chemiluminescence.
Tubulin was used as a loading control.
Detection of changes in mRNA expression
of proinflammatory genes upon stimulation with TNF-
a, IL-1b or Pam3CSK4
Changes in the expression of TLR2 target genes IL-6
and IL-8 were measured in cells from five to seven
patients (grade 3–4) which were first rendered serum free
for 2 h before stimulating them for 18 h with recombi-
nant IL-1b (5 ng/ml), TNF-a (10 ng/ml) or the known
TLR2 ligand Pam3CSK4 (100 ng/ml; InvivoGen/Lab
Force, Switzerland) in serum-free medium with strepto-
mycin (50 lg/mL), ampicillin (125 ng/mL) and poly-
myxin B (which binds any possible LPS contamination;
10 lg/ml, Sigma-Aldrich, Switzerland). The concentra-
tion for Pam3CSK4 was chosen based on preliminary
studies which investigated cytotoxicity and inflammatory
potential (see Supplementary Figure S1a/b/c). Changes in
gene expression of IL-6 and IL-8 after 18 h of treatment
were analyzed as described above (for primer details see
Table 1).
Analysis of TLR activation upon stimulation with TNF-
a, IL-1b or Pam3CSK4
To detect whether IL-1b and TNF-a stimulation leads to
activation of TLR2 (the most appropriate TLR based on
the above mentioned results), a specific TLR2 neutral-
izing antibody (pab-hstlr2; InvivoGen/Lab Force, Swit-
zerland) at a concentration of 5 lg/ml was used to
inhibit TLR2 binding capacity. Cell cultures of four
patients (grade 3–4) were rendered serum free for 2 h
and then preincubated with TLR2 neutralizing antibody
for 1 h, followed by adding IL-1b (5 ng/ml), TNF-a
(10 ng/ml) or Pam3CSK4 (100 ng/ml); the respective
IgG control (rat IgG2b, Biolegend/LucernaChem, Swit-
zerland) was included and data were calculated relative
to this control. The concentration of TLR2 neutralizing
antibody was chosen based on preliminary data, obtained
by the measurement of changes in mRNA levels of IL-6
and IL-8 after dose-dependency experiment with pab-
hstlr2/Pam3CSK4 (data not shown). Changes in gene
expression of IL-6 and IL-8 after 18 h of treatment were
analyzed as described before.
Analysis of down-stream activation of NF-jB
upon stimulation with TNF-a, IL-1b or Pam3CSK4
As TLR activation can be linked to NF-jB activation, two
methods (immunocytochemistry, transcription factor
assay) were used to determine NF-jB activation upon
stimulation with IL-1b, TNF-a and Pam3CSK4.
Immunocytochemistry was used to detect nuclear
translocation of p65 after stimulating cells seeded in
24-well plates with IL-1b (5 ng/ml), TNF-a (10 ng/ml) or
Pam3CSK4 (100 ng/ml) (all 1 h), with or without pre-
treatment with TLR2 neutralizing antibody (1 h) as
described above. An untreated control, a negative control
(no primary antibody) as well as an IgG control were
included and a previously described method for staining
was used [32]. Briefly, cells (grade 3–4) were fixed in ice-
cold methanol, washed, blocked (1 % BSA, 0.1 % Triton-
X in PBS) and incubated with p65 antibody (sc-372, Santa
Cruz) for 60 min before fluorescence labeling with a spe-
cific secondary antibody. Nuclear counterstaining with
DAPI was also performed.
Immunocytochemistry results were confirmed by a
commercial NF-jB (p65) transcription factor assay (Cay-
man), which allows measuring NF-jB (p65) binding
activity in nuclear extracts isolated from IVD cells that
underwent the same treatment as described above. All
absorbance measurements were carried out at 655 nm.
Analysis of the role of HSP60, HSP70 and HMGB1
in TLR signaling during IVD inflammation
To identify whether the stress-related proteins (HSP60,
HSP70, HMGB1) play a role in TLR signaling during
inflammatory disc disease, changes in the mRNA expres-
sion of HSP60, HSP70 and HMGB1 upon stimulation with
IL-1b and TNF-a were analyzed in human disc cells (grade
3–4) by real-time RT-PCR. Furthermore, IVD cells were
rendered serum free for 2 h and then incubated with
recombinant human HSP60 (Enzo Life Sciences: 0.1, 1.0
or 10 lg/ml), HSP70 (Enzo Life Sciences: 0.1, 1.0 or
10 lg/ml) or HMGB1 (Abnova: 0.05, 0.1 or 0.5 lg/ml) (all
in DMEM/F12 with penicillin, streptomycin, ampicillin
and polymyxin as described above) before measuring
changes in the expression of IL-6 and IL-8 by real-time
RT-PCR (after 18 h).
Statistical analysis
Quantified results were statistically analyzed by Mann–
Whitney U test for comparison between treatment groups
and control group as well as by ANOVA and Tukey–
Kramer HSD test for comparison between different groups,
1882 Eur Spine J (2014) 23:1878–1891
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using the SPSS Statistics Program (SPPS 20.0.0). For all
tests, the significance level was set to p \ 0.05.
Results
Basal TLR gene expression
Basal expression of TLRs was investigated in cultured,
but untreated IVD cells of 6 different donors. As data are
presented as DCt values, low values represent high
expression and vice versa. We found TLR1, 6 and 10 to
be highly expressed (DCt values \10), while mRNA
expression of TLR2, 3, 4, 5 and 9 was lower (DCt values
[10) (Fig. 1a). TLR7 and TLR8 could not be detected in
human IVD cells. As TLR2, 3 and 4 have been demon-
strated to play a major role in osteoarthritis and rheuma-
toid arthritis [8, 29, 33], these TLRs—together with the
highly expressed TLRs (TLR1/6/10)—were further
investigated.
Changes in TLR mRNA expression with the degree
of IVD degeneration
Tissue samples with different degrees of degeneration (4
grades, n = 5–10 in each grade) were analyzed for TLR1,
2, 3, 4, 6 and 10 mRNA expression. While TLR3 and
TLR10 expression did not depend on the degree of
degeneration (see Supplementary Figure S2a/b), mRNA
expression of TLR1 (Fig. 1b) TLR2 (Fig. 1c), TLR4
(Fig. 1d) and TLR6 (Fig. 1e) showed a statistically sig-
nificant alteration during degeneration, with an increase in
expression in the moderate and severe group. TLR1, TLR2,
TLR4 and TLR6 were thus chosen for further
investigations.
Changes in TLR gene expression after stimulation
with TNF-a and IL-1b
In the next step, we analyzed whether the expression of
TLR1, TLR2, TLR4 and TLR6 is induced by TNF-a or
Fig. 1 Basal TLR mRNA expression and changes in TLR mRNA
expression with the degree of IVD degeneration. Basal gene
expression levels of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,
TLR9 and TLR10 in expanded but untreated human disc cells (a),
measured by real-time RT-PCR and calculated by the DCt method.
Low values are thus representative of high expression and vice versa.
Individual data points of six independent donors. TLR7/8 was not
detectable. Gene expression of TLR1 (b), TLR2 (c), TLR4 (d) and
TLR6 (e) in IVD biopsies with different degrees of degeneration
(1 = healthy; 2 = mild degeneration; 3 = moderate degeneration;
4 = severe degeneration), measured by real-time RT-PCR and
calculated by the 2-DCt method. Individual data points of 5–10
independent donors in each group. Asterisks indicate statistical
significance between indicated groups (i.e. grades of degeneration)
with p \ 0.05. (For TLR3 and TLR10 see Supplementary Figure S2a/
b)
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IL-1b. When treating cells with 10 ng/ml TNF-a or 5 ng/
ml IL-1b or for 2, 6 or 18 h, we could observe an
increase in TLR1 expression with TNF-a treatment (3.2
fold after 6 h; 4.9 fold after 18 h) (Fig. 2a), but not with
IL-1b treatment (Fig. 2b). TLR2 expression increased
with both, TNF-a (Fig. 2c) and IL-1b (Fig. 2d), with the
highest effects after 18 h. The increase in TLR2
expression after TNF-a treatment (108.2 fold, 18 h) was
higher than after IL-1b treatment (7.5 fold, 18 h). TNF-a
treatment also slightly induced TLR4 expression (2.1
fold, 18 h) (Fig. 2e), while stimulation with L-1b had no
effect on TLR4 mRNA levels (Fig. 2f). No changes were
observed for TLR6 expression after any treatment and at
any time point (Fig. 2g, h).
Fig. 2 Changes in TLR mRNA expression upon stimulation with
TNF-a or IL-1b (time course). Fold changes in gene expression of
TLR1 (a, b), TLR2 (c, d), TLR4 (e, f) and TLR6 (g, h) after
stimulation with 10 ng/ml TNF-a (a, c, e, g) or 5 ng/ml IL-1b (b, d, f,
h) for 2, 6 or 18 h, measured by real-time RT-PCR and calculated by
the 2-DDCt method. Changes are calculated relative to untreated control
cells. Mean ± SEM of five independent donors. Asterisks indicate
statistical significance relative to untreated control with p \ 0.05
1884 Eur Spine J (2014) 23:1878–1891
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Stimulation of disc cells with different concentrations of
TNF-a or IL-1b for 18 h resulted in changes in TLR gene
expression similar to the time course experiments. TNF-a
caused a dose-dependent increase in TLR1 expression
(three to fourfold) (Fig. 3a), whereas IL-1b had no effect at
any concentration (Fig. 3b). TNF-a and IL-1b both
Eur Spine J (2014) 23:1878–1891 1885
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induced TLR2 expression in a direct, concentration-
dependent manner. Upon TNF-a treatment, TLR2 expres-
sion was induced 119.4 fold (Fig. 3c; 100 ng/ml), while
IL-1b treatment only caused an 18.9 fold induction
(Fig. 3d, 10 ng/ml). TLR4 expression was increased 2.1
fold by TNF-a treatment (Fig. 3e, 100 ng/ml), whereas IL-
1b treatment resulted in a slight reduction in mRNA
expression at all concentrations (Fig. 3f). TLR6 expression
was neither regulated by TNF-a nor by IL-1b (Fig. 3g, h).
While TLR1 and TLR4 were slightly induced upon
TNF-a treatment, TLR2 was strongly induced with both,
IL-1b and TNF-a and was thus chosen for all further
investigations.
Supplementary material As TLR3 has been described to be
of importance in cartilage disease, changes in TLR3 expres-
sion upon stimulation with TNF-a and IL-1b were also
measured. As shown in Supplementary Figure S3a/b, TNF-a
treatment induced TLR3 expression at later time points and
higher concentrations (up to tenfold), while IL-1b treatment
had minor effects (see Supplementary Figure 3a–d).
Changes in TLR2 protein expression after stimulation
with TNF-a and IL-1b
On the protein level, stimulation with IL-1b and TNF-a
also resulted in increased levels of TLR2 expression
bFig. 3 Changes in TLR mRNA expression (concentration depen-
dency) and in TLR2 protein expression upon stimulation with TNF-a
or IL-1b. Fold changes in gene expression of TLR1 (a, b), TLR2 (c,
d), TLR4 (e, f) and TLR6 (g, h) after stimulation with different
concentrations of TNF-a (a, c, e, g) or IL-1b (b, d, f, h) for 18 h,
measured by real-time RT-PCR and calculated by the 2-DDCt method.
Changes are calculated relative to untreated control cells. Mean ±
SEM of five independent donors. Asterisks indicate statistical
significance relative to untreated control with p \ 0.05. As TLR2
was regulated most on the gene expression level, TLR2 was chosen
for protein expression analysis after stimulation with TNF-a (100 ng/
ml) or IL-1b (10 ng/ml) for 24 h (i). Stimulated samples are shown
relative to untreated control cells, detected by immunoblotting (three
independent donors, one representative picture). Extracts from THP1
cells are used as positive controls. The image has been cropped to
improve clarity. Used TLR2 antibody: AF2616, R&D Systems,
0.2 lg/ml
Fig. 4 Changes in mRNA expression of IL-6 and IL-8 upon
stimulation with TNF-a, IL-1b or Pam3CSK4 with or without
TLR2 neutralizing antibody. Fold change in gene expression of the
TLR2 target genes IL-6 (a) and IL-8 (b) after stimulation with 10 ng/
ml TNF-a, 5 ng/ml IL-1b or 100 ng/ml Pam3CSK4 for 18 h (without
TLR2 neutralizing antibody), relative to untreated control. Data
obtained by real-time RT-PCR and calculated by the 2-DDCt method.
Mean ± SEM of five to seven independent donors. Asterisks indicate
statistical significance relative to untreated control with p \ 0.05.
Prestimulation with 5 lg/ml neutralizing antibody (pabhstlr2, Inviv-
ogen) for 1 h before treatment with either 10 ng/ml TNF-a, 5 ng/ml
IL-1b or 100 ng/ml Pam3CSK4 for 18 h. Fold change in gene
expression of the TLR2 target genes IL-6 (c) and IL-8 (d) after 18 h,
relative to the respective IgG control (expression with IgG control is
set to 100 %). Data obtained by real-time RT-PCR and calculated by
the 2-DDCt method. Mean ± SEM of four independent donors.
Asterisks indicate statistical significance relative to IgG control with
p \ 0.05
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(Fig. 3i; human THP1 cells as positive control). TLR2 was
chosen for protein detection as it showed most prominent
changes on the mRNA level (compared to TLR1 and
TLR4, which were altered only slightly). Furthermore,
commercial antibodies for the detection of TLR1 and
TLR4 did not provide satisfactory results, either due to
unspecificity or insensitivity [16] or because of too low
expression levels in disc cells.
Changes in mRNA expression of proinflammatory
genes after stimulation with TNF-a, IL-1b
or Pam3CSK4
When stimulating cells with 10 ng/ml TNF-a, 5 ng/ml IL-
1b or 100 ng/ml Pam3CSK4, an increase of IL-6 and IL-8
was observed: IL-6 mRNA expression was increased 120.1
fold by TNF-a, 1689.1 fold by IL-1b and 10707.7 fold by
Pam3CSK4 (see Fig. 4a); IL-8 mRNA expression was
increased 218.5 fold by TNF-a, 682.3 fold by IL-1b and
9202.2 fold by am3CSK4 (see Fig. 4b).
TLR2 activation upon stimulation with TNF-a, IL-1b
or Pam3CSK4
When prestimulating cells for 1 h with 5 lg/ml pab-
hstlr2 (a specific TLR2 neutralizing antibody) before
adding TNF-a, IL-1b or Pam3CSK4, levels of IL-6
were decreased in case the of Pam3CSK4 treatment
(-2.4 fold: 100 ? 41.9 %), but not in the case of
TNF-a or IL-1b treatment (Fig. 4c). Similarly, the
TLR2 neutralizing antibody reduced levels of IL-8 upon
stimulation with Pam3CSK4 (1.7 fold: 100 ? 60.2 %),
but not upon stimulation with TNF-a or IL-1b (Fig. 4d).
Note that cells under inflammatory conditions, i.e. cells
stimulated with Pam3CSK4, TNF-a or IL-1b plus the
appropriate IgG control were used as a reference and set
to 100 %.
NF-jB activation upon stimulation with TNF-a, IL-1b
or Pam3CSK4
TNF-a and IL-1b caused nuclear translocation of p65 after
60 min of stimulation, which was not prevented by pre-
treatment with the TLR2 neutralizing antibody as shown by
immunocytochemistry (Fig. 5a) and measurement of DNA
binding activity (Fig. 5b). While immunocytochemistry did
not reveal distinct effects for Pam3CSK4, the transcription
factor assay clearly indicated the absence of increased
DNA binding activity upon stimulation with Pam3CSK4
(Fig. 5a, b). This provides evidence that Pam3CSK4,
despite activating TLR2, does not cause down-stream
activation of NF-jB.
Role of HSP60, HSP70 and HMGB1 in TLR signaling
during IVD inflammation
We have previously demonstrated the expression of HSP60,
HSP70 and HMGB1 in human IVD biopsies, although no
clear correlation between expression levels and the degree
of degeneration could be found (unpublished data). In this
study, we found that stimulation of human IVD cells with
IL-1b (5 ng/ml) and TNF-a (10 ng/ml) did not alter the
expression of HSP60 and only very slightly induced
expression of HSP70 (1.5 fold increase with IL-1b) and
HMGB1 (1.3 fold with TNF-a) (Supplementary Figure 4a–
c). HSPs and HMGB1 had minor inflammatory properties in
human IVD cells. Stimulation with recombinant HSP60 did
not have any effect and HSP70 only slightly induced IL-6
(3.6 fold) increase and IL-8 (2.7 fold increase), but only at
the highest concentration of 10 lg/ml. In contrast, HMGB1
caused a minor inhibition of IL-6 expression (2.2 fold
decrease) and had no effect on IL-8 mRNA levels (see
Supplementary Figure 5a-f).
Discussion
In the present study, we found that TLR1, 2, 3, 4, 5, 6, 9
and 10 were expressed in human IVD cells, while only
TLR1, TLR2, TLR4, and TLR6 were dependent on the
degree of IVD degeneration. So far, only TLR2 and TLR4
have been described by us [34, 35] and others [36–38] to be
expressed in human [34, 35, 37, 38] or in bovine IVD cells
[36–38]. TNF-a, a physiological inflammatory signal,
slightly induced TLR1 and TLR4 gene expression, whereas
it strongly increased TLR2 gene and protein expression;
expression of TLR3 (although not correlating to the degree
of degeneration) was also induced by TNF-a. IL-1b also
induced TLR2 gene and protein expression, but not TLR1
and TLR4 gene expression. Although IL-1b and TNF-a
caused an increase in TLR2, these mediators did not acti-
vate TLR2 expression, i.e. they do not act as TLR2 ligands
in human IVD cells, whereas Pam3CSK4 does.
This is, to our knowledge, the first study that investi-
gates the expression and regulation of TLRs in human IVD
cells in a comprehensive manner. Our results clearly
indicate that IL-1b and TNF-a, two of the major proin-
flammatory cytokines that are present during degenerative
IVD disease [4, 39], induce TLR2 gene and protein
expression. On the other hand, only a slight induction of
TLR4 gene expression upon TNF-a stimulation was
observed. Similarly, a prominent up-regulation of TLR2
but no regulation of TLR4 has been described upon stim-
ulation with IL-1b and especially TNF-a in tenocytes [40].
Kim et al. [41] described a slight but significant induction
of TLR2 mRNA expression (twofold increase) with IL-1b
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treatment and comparable results were published by Ell-
man et al. [37], using IVD cells. In human MSCs,
inflammation (caused by a cocktail of IL-1b, TNF-a, INF-
a, and INF-c) increased TLR2 and TLR4 expression, also
with highest effects for TLR2 [42]. When comparing the
responsiveness of TLR2 and TLR4 to IL-1b treatment in
human epithelial cells and OA chondrocytes, it was found
that—similar to our own data—only TLR2 expression was
up-regulated [11, 43]. Despite similarities in the above
described TLR data, variances amongst cell types seem to
exist. Therefore, it is likely that the chondrocyte-like NP
cells and the fibroblast-like AF cells show certain differ-
ences in both, the expression and regulation of TLRs,
which we were not able to detect using human surgical disc
material. While human biopsies cannot be accurately sep-
arated into NP and AF, experiments on e.g. bovine IVDs
could elucidate zonal differences.
TLRs have long been described to detect pathogens and
thus activate the innate immune system [13]. Due to its
ability to build heterodimers with other TLRs and to use
co-receptors for the recognition of certain molecules,
TLR2 is proposed to have the largest number of ligands
[44]. TLR2 ligands thus not only include bacterial com-
ponents (e.g. peptidoglycan, lipoteichoic acid or lipoara-
binomannan), but also endogenous components such as
heat shock proteins, HMGB1 or matrix fragments
Fig. 5 Activation of NF-jB
upon stimulation with TNF-a,
IL-1b or Pam3CSK4.
Prestimulation with 5 lg/ml
neutralizing antibody
(pabhstlr2) for 1 h before
treatment with either 10 ng/ml
TNF-a, 5 ng/ml IL-1b or
100 ng/ml Pam3CSK4 for 1 h.
For detection of p65, a specific
NF-jB/p65 antibody was used
for immunocytochemistry, with
a representative picture of three
independent donors being
shown (a). P65/NF-jB binding
activity in nuclear extracts was
determined by a commercial
transcription factor assay.
Mean ± SD of three
independent donors. Asterisks
indicate statistical significance
relative to untreated control
with p \ 0.05 and hash keys
indicate statistical significance
to the respective neutralizing
antibody group with p \ 0.05
(b)
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(summarized in [45]), which are produced in case of
stress, inflammation or disease [46–48]. As IL-1b and
TNF-a induced TLR2 expression in IVD cells in our
experiments as well as in other cell types as described in
already published studies [11, 40–43], we were interested
in understanding whether IL-1b or TNF-a directly activate
TLR2 via ligand–receptor-binding—instead of solely
leading to an inflammatory environment that favors the
production of endogenous TLR ligands. However, our
results using a chemical inhibitor of TLR2 (i.e. a specific
TLR2 neutralizing antibody) clearly show that neither IL-
1b nor TNF-a activate TLR2 in human IVD cells. Fur-
thermore, IL-1b and TNF-a activate the transcription
factor NF-jB (i.e. cause nuclear translocation of p65), but
this effect was not mediated via the TLR2 pathway, thus
further confirming that IL-1b and TNF-a do not act as
TLR ligands.
Although TLR2 is neither activated directly by IL-1b
nor by TNF-a, TLRs may still play a major role in
inflammatory signaling during degenerative IVD disease.
As described above, the inflammatory environment in the
IVD in vivo may cause induction of endogenous TLR
ligands, similar to cartilage (reviewed in [33]). From the
large variety of possible endogenous ligands, we tested
whether the stress-related proteins HSP60, HSP70 and
HMGB1, which are expressed in human IVD tissue
(unpublished data), play a role in TLR signaling during
inflammatory IVD disease. However, IVD inflammation
(i.e. IL-1b/TNF-a) did not increase the expression of the
analyzed candidates in human IVD cells. Furthermore,
HSP60, HSP70 and HMGB1 showed no inflammatory
capacity, indicating that they do not play a role in TLR/NF-
jB signaling in the human IVD. However, IL-1b and TNF-
a may lead to formation of other potential endogenous
ligands. In fact, IL-1b and TNF-a has been shown to
stimulate expression of hyaluronidases and thus accumu-
lation of hyaluronic acid fragments [49], whose inflam-
matory properties have been described e.g. in cartilage [48,
50]. Indeed, we were able to demonstrate most recently that
small fragments of hyaluronic acid (6-12 disaccharides) act
as TLR2 ligands and thus induce an inflammatory and
catabolic cascade by downstream activation of the MAP
Kinase pathway [16].
Importantly, TLR-ligand interaction can lead to activa-
tion of NF-jB and MAPK, which has also been detected
under specific conditions in IVD cells in vitro and in vivo
(reviewed in [7, 33]). The potential role for TLRs in
degenerative IVD disease is further underlined by the fact
that TLRs control the expression of numerous proinflam-
matory cytokines (e.g. IL-1, IL-6, TNF-a), chemokines
(e.g. IL-8) and matrix metalloproteinases [8, 51, 52] that
are all fundamental in the pathophysiological processes of
the IVD [53]. As our study demonstrated that
proinflammatory cytokines can induce TLR2 expression
and as TLRs mediate inflammatory and catabolic responses
upon ligand binding (e.g. via activation of MAPK as
demonstrated for hyaluronic acid fragments [16]) a self-
sustaining inflammatory loop may exist under certain
conditions in vivo. Therefore, the in vivo formation of
endogenous TLR ligands such as hyaluronic acid fragments
[54] or other yet unknown endogenous proteins can lead to
the activation of the TLR signaling pathway and thus
downstream stimulation of catabolic and inflammatory
mediators. Interfering with the TLR signaling pathway, e.g.
via inhibition of TLR2, could provide a molecular
approach to prevent further tissue damage and inflamma-
tion, thus possibly representing a novel therapeutic option
to treat painful degenerative disc disease.
Conclusion
In this study, we provide evidence that several TLRs are
expressed in human IVD cells, with TLR1, TLR2, TLR4
and TLR6 expression being dependent on the degree of
IVD degeneration. TLR1 and TLR4 gene expression, and
more strongly TLR2 gene and protein expression is
increased by proinflammatory cytokines (IL-1b, TNF-a),
although these substances do not activate TLR2. However,
we were able to demonstrate most recently that small
hyaluronic acid fragments act as TLR2 ligands, thus
inducing inflammatory and catabolic processes. Based on
these results, therapeutic targeting of TLR2 could represent
a successful strategy to treat patients with painful degen-
erative disc disease.
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